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ﺐﻠﻘﻟﺍﺽﺍﺮﻣﺃﺭﻮﻬﻇﻲﻓﺐﺒﺴﺘﺘﻟﺔﻴﻨﻴﺠﻟﺍﻭﺔﻴﺤﺼﻟﺍﻭﺔﻴﺌﻴﺒﻟﺍﻞﻣﺍﻮﻌﻟﺍﻞﻋﺎﻔﺘﺗ
.ﻢﻟﺎﻌﻟﺍﻝﻮﺣﺕﺎﻴﻓﻮﻠﻟﺔﺴﻴﺋﺮﻟﺍﺏﺎﺒﺳﻷﺍﻦﻣﺔﻴﺟﺎﺘﻟﺍﺐﻠﻘﻟﺍﺽﺍﺮﻣﺃﺮﺒﺘﻌﺗﻭ.ﺔﻴﺟﺎﺘﻟﺍ
ﺎﻬﻤﻫﺃﻦﻣﺓﺮﻴﺜﻛﻞﻣﺍﻮﻋﺔﻴﺟﺎﺘﻟﺍﺐﻠﻘﻟﺍﺽﺍﺮﻣﻷﺔﺒﺒﺴﻤﻟﺍﺔﻳﺪﻴﻠﻘﺘﻟﺍﻞﻣﺍﻮﻌﻟﺍﻞﻤﺸﺗﻭ
.ﻡﺪﻟﺍﻲﻓﻥﻮﻫﺪﻟﺍﺔﺒﺴﻧﻉﺎﻔﺗﺭﺍﻭ،ﻦﻴﺧﺪﺘﻟﺍﻭ،ﻱﺮﻜﺴﻟﺍﻭ،ﻡﺪﻟﺍﻂﻐﺿﻉﺎﻔﺗﺭﺍﻭ،ﺮﻤﻌﻟﺍ
ﺔﺒﺴﻧﻦﻣﺮﻴﺒﻛﻞﻜﺸﺑﻭﺾﻔﺨﻳﺔﻴﻌﻴﺒﻄﻟﺍﺎﻬﺗﺎﻳﻮﺘﺴﻣﻲﻓﻥﻮﻫﺪﻟﺍﻰﻠﻋﻅﺎﻔﺤﻟﺍﻥﺇ
ﻰﻠﻋﻁﺎﺒﺗﺭﻻﺍﺕﺎﺳﺍﺭﺩﺖﻤﻤﺻﺪﻗﻭ.ﻦﻴﻳﺍﺮﺸﻟﺍﺐﻠﺼﺗﻭﺐﻠﻘﻟﺍﺽﺍﺮﻣﺄﺑﺔﺑﺎﺻﻹﺍ
ﻡﻮﻨﻴﺠﻟﺍﻞﺴﻠﺴﺗﻲﻓﺕﺎﻓﻼﺘﺧﻻﺍﻰﻠﻋﻑﺮﻌﺘﻠﻟﺓﺯﺎﺤﻨﻣﺮﻴﻏﺔﻘﻳﺮﻄﺑﻡﻮﻨﻴﺠﻟﺍﻯﻮﺘﺴﻣ
،ﺓﺪﻘﻌﻣﺽﺍﺮﻣﺄﺑﺔﺑﺎﺻﻹﺍ(ﻦﻣﻪﻴﻤﺤﺗﻭﺃ)ﺮﻄﺧﻲﻓﻥﺎﺴﻧﻹﺍﻊﻀﺗﺪﻗﻲﺘﻟﺍ،ﻱﺮﺸﺒﻟﺍ
ﺎﻤﻟﺔﻌﺟﺍﺮﻤﻟﺍﻩﺬﻫﻲﻓ.ﻱﺮﻜﺴﻟﺍﻭﺔﻴﺟﺎﺘﻟﺍﺐﻠﻘﻟﺍﺽﺍﺮﻣﺄﻛﺔﻴﻨﻴﺠﻟﺍﺏﺎﺒﺳﻷﺍﺓﺩﺪﻌﺘﻣﻭ
ﻪﻨﻋﺮﻔﺳﺃﺎﻤﻟﺕﺍﺪﺠﺘﺴﻤﻟﺍﺶﻗﺎﻨﻧﻭﺀﻮﻀﻟﺍﻂﻠﺴﻧ،ﻥﻵﺍﻰﺘﺣﺕﺎﺳﺍﺭﺩﻦﻣﻪﻠﻤﻋﻢﺗ
ﺕﺮﻬﻇﺃﻲﺘﻟﺍﻡﻮﻨﻴﺠﻟﺍﻞﺴﻠﺴﺗﻲﻓﺓﺩﺪﻌﺘﻣﺕﺎﻓﻼﺘﺧﺍﻑﺎﺸﺘﻛﺍﻲﻓﺔﻴﻨﻘﺘﻟﺍﻩﺬﻫﻡﺍﺪﺨﺘﺳﺍ
ﻩﺬﻫﺪﻋﺎﺴﺗﻥﺃﻦﻜﻤﻳﻒﻴﻛﻭ،(ﺓﺩﺎﻳﺯﻭﺃﺺﻘﻧ)ﻢﺴﺠﻟﺍﻲﻓﻥﻮﻫﺪﻟﺍﺕﺎﻳﻮﺘﺴﻤﺑﺎﻃﺎﺒﺗﺭﺍ
ﻲﻓﺓﺪﻋﺎﺴﻤﻟﺍﻲﻓﻼﺒﻘﺘﺴﻣﻡﺪﺨﺘﺴﺗﺪﻗ،ﺔﻴﺟﻼﻋﻑﺍﺪﻫﺃﻰﻠﻋﻑﺮﻌﺘﻟﺍﻲﻓﺞﺋﺎﺘﻨﻟﺍ
.ﻡﺪﻟﺍﻲﻓﺔﻌﻔﺗﺮﻤﻟﺍﻥﻮﻫﺪﻟﺍﻭﻝﻭﺮﺘﺴﻟﻮﻜﻟﺍﺕﺎﻳﻮﺘﺴﻣﺾﻴﻔﺨﺗ
؛ﻲﻤﺤﺷﻦﻴﺗﻭﺮﺑ؛ﻡﻮﻨﻴﺠﻟﺍﻯﻮﺘﺴﻣﻰﻠﻋﻁﺎﺒﺗﺭﻻﺍﺕﺎﺳﺍﺭﺩ:ﺔﻴﺣﺎﺘﻔﻤﻟﺍﺕﺎﻤﻠﻜﻟﺍ
ﻝﻭﺮﺘﺴﻟﻮﻜﻟﺍ؛ﻱﺪﻴﺼﻌﻟﺍﺐﻠﺼﺘﻟﺍ؛ﺔﻴﺟﺎﺘﻟﺍﺐﻠﻘﻟﺍﺽﺍﺮﻣﺃ
tcartsbA
ssorca rellik rojam a si )DAC( esaesid yretra yranoroC
fo tcurtsnoc a si DAC fo sisenegohtap ehT .dlrow eht* Corresponding address: Center for Genetics and Inherited Dis-
eases, Taibah University, Almadinah Almunawwarah, KSA.
E-mail: nmontashri@taibahu.edu.sa (N.A.M. Almontashiri)
Peer review under responsibility of Taibah University.
Production and hosting by Elsevier
1658-3612  2015 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah University. T
(http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.10multiple predisposing elements, including environmental,
health and genetic factors. Traditional risk factors for
CAD include age, hypertension, diabetes, smoking, and
dyslipidaemia. Optimizing the lipid levels to within the
normal range significantly and drastically reduces the risk
of coronary atherosclerosis. Genome-wide association
studies (GWASs) promise to accurately identifying the
variants that increase or decrease the risks of multiple
and complex disorders. In this review, we shed light on
and discuss the recent GWASs of lipoprotein genetics and
how such studies have provided new pathways and
pharmacological targets that might enable the control the
pathological plasma cholesterol levels.
Keywords: Atherosclerosis; CAD; Cholesterol; GWAS; Lip-
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Coronary artery disease (CAD) is the leading cause of
death in the western world1 and is also a major cause of
mortality in other countries, including Saudi Arabia.2 CAD
is an age-progressive disease; although fewer than 10% of
individuals exhibit symptoms of CAD before the age of 50,
intravascular ultrasound examinations have revealed that 1 in
6 adolescents and 85% of persons over the age of 50 havehis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2015.01.012
N.A.M. Almontashiri and M. Hannan 267measurable coronary atherosclerosis.3 Using angiograms, the
burden of atherosclerosis can be scored by the number of
affected vessels (i.e., 0, 1, 2 and 3-vessel disease) and used
to measure the severity of CAD.3 Moreover, CAD is a silent
killer because the majority of people who experience
myocardial infarction (MI) do not experience symptoms
prior to the infarction despite having extensive coronary
atherosclerosis. Several modifiable factors increase the risk
of CAD and MI, including smoking, diabetes mellitus,
circulating cholesterol levels, hypertension, and obesity.
Treating these risk factors reduces the mortality due to
CAD by 30e40%.4 In contrast, studies of twins have
revealed that up to 50% of the risk for CAD is genetic,5
which suggests that the identification of the responsible
genetic factors will be useful for predicting individual risks
for CAD. Understanding the molecular pathways that are
affected by these genetic factors might also aid the
identification of novel targets for therapeutic treatments for
the disease. The traits associated with cardiovascular
disease risk factors, such as coronary artery and plasma
lipoprotein levels, exhibit complex inheritances that are
suggestive of interactions between multiple genes and non-
genetic factors such as the environment.6 To unravel and
dissect these complexities, extensive data collection and
analyses from large samples are required to genetically map
these complex traits. One such approach that allowed us to
map these complex traits is the genome wide association
study (GWAS).
In 2007, using microarrays of single nucleotide poly-
morphisms (SNPs) to genotype large numbers of cases and
controls, McPherson et al. identified the first common ge-
netic variants on chromosome 9p21.3 that increase CAD
risk7 using a GWAS. Several other large GWAS
investigations have confirmed this association with CAD
and/or extended it to MI.8e10 Dandona et al. recently
showed that this locus promotes coronary atherogenesis
rather than plaque rupture because the number of risk
alleles is strongly correlated with the severity of CAD but
not with acute coronary syndrome among CAD cases
defined by coronary angiography.11 However, the
mechanism by which the 9p21.3 locus increases the risk of
CAD remains elusive.12 To date, more than 30 loci have
been identified by GWAS, including 13 novel loci that were
discovered by a large international consortium called the
CARDIoGRAM.13 Importantly, using only 12 of these
loci, Davies et al. showed cardiovascular risk prediction
could be improved beyond traditional risk factors analysis.14
Factors that increase the risk for coronary atherosclerosis
include high serum cholesterol concentrations, high levels of
low density lipoprotein (LDL) and very low density lipo-
protein (VLDL), and low levels of high density lipoprotein
(HDL).15e17 Intervention trials have shown that reducing the
levels of LDL-C in particular can reduce CAD risk18 and the
rate of progression of coronary artery stenosis as
demonstrated angiographically.19 In contrast, HDL-C
levels are inversely related to CAD risk.20 In dyslipidaemia,
the levels of lipids or lipoproteins are abnormal due to
genetic and/or environmental conditions that alter the
biogenesis or the metabolism of the lipoproteins in the
circulation.
GWASs have allowed major advances the discovery of
numerous risk loci that affect blood lipoprotein levels andincrease the risk of coronary atherosclerosis. Based on their
locations within or in close proximity to known21,22 or
previously unknown genes that affect lipoproteins levels,23
these variants have increased our knowledge about the
control and involvement of lipoproteins in the process of
atherosclerosis. We next review examples, in chronological
order, of the successes of GWASs in identifying novel loci
that are associated with CAD risk and that affect
lipoprotein levels and how some of these loci might be
involved in new pathways that lead to CAD. Notably, the
majority of the relevant studies used cohorts defined by
coronary angiography to measure atherosclerosis.The unbiased power of GWASs in identifying new variants
In 2008, Kathiresan and colleagues used genotype impu-
tation and meta-analysis to combine three genome-wide
surveys to scan for and identify loci that influence lipid
concentrations and the risk of coronary artery disease.24
These authors identified several loci that are associated
with lipoprotein levels. Interestingly, the 11 independent
common variants that were found to be associated with
increased LDL cholesterol concentrations in their study
also exhibited significant association with the risk of CAD.
These loci are involved in many aspects of lipid
metabolism. For example, PCSK9 is required for the
clearance of the LDL receptor, and the LDLR is required
for LDL uptake and clearance. PCSK9 has been shown to
be elevated during acute myocardial infarction in two
independent studies.32 Collectively, these results suggest
that the cumulative and the lifetime effects of these
multiple common variants contribute to polygenic
dyslipidaemia. These findings have been replicated by
others.22,25
In 2009, Robert Clarke and colleagues identified the in-
dependent relevance of two common variants (rs10455872
and rs3798220) of the LPA gene to CAD.21 Together, these
two variants explained 36% of the total variation in Lp(a)
lipoprotein levels. These authors found that the effects of
these variants on CAD risk and Lp(a) lipoprotein levels are
correlated. This linear dose-response relationship supports
a pathogenic role of elevated Lp(a) lipoprotein levels in CAD
risk. This study is consistent with earlier studies that
demonstrated a clear association between Lp(a) and CAD
severity.26,27
In 2010, Kathiresan and colleagues performed a large
scale GWAS searching for common variants associated with
the plasma lipids in European and non-European pop-
ulations.25 First, these authors performed a meta-analysis of
46 lipid GWASs that comprised more than 100,000 in-
dividuals of European descent. They were able to identify 95
significantly associated loci that reached the genome wide
significance levels of<5 108. Of these loci, 59 were found
to exhibit genome-wide significant associations with lipid
traits for the first time. Among these 59 novel loci, 22
exhibited genome-wide significant associations with LDL-
C, 31 with HDL-C, and 16 with TG. To identify addi-
tional SNPs that exhibited independent associations at each
of the identified loci, these authors performed conditional
association analyses for each of the four lipid traits. Using
this approach, they identified 26 additional secondary loci.
Usefulness of GWAS in lipoprotein metabolism268When these secondary SNPs were combined with the pri-
mary SNPs, the overall mapped variants explained 12.1%
(HDL-C), 12.2% (LDL-C), and 9.6% (TG) of the total
variances in each lipid trait in the FraminghamHeart Study,
which represented 25e30% of the genetic variance for each
lipoprotein trait. To gain further insight into how the newly
identified variants affected plasma lipid concentration, these
authors examined the correlations between each of the pri-
mary SNPs at the 95 loci and expression levels of the tran-
scripts located within 500 kilobases of the SNPs in three
different tissues that are relevant to these lipoproteins. They
were able to identify tissue-specific effect of these SNPs on
the lipids. These SNPs were relevant to other non-European
populations (i.e., East Asians, South Asians and African
Americans). To gain further insight into the clinical
importance and relevance of these loci, they examined which
of the lipid loci were associated with the risk of CAD. Four
novel CAD-associated loci (i.e., IRS1, C6orf106, KLF14
and NAT2) that are related to TG and/HDL-C were iden-
tified. These findings might indicate that these variants exert
their effects on CAD by affecting lipoproteins or tri-
glycerides (CAD risk factors) via direct or indirect pleio-
tropic effects. Next, these authors examined whether the
GWAS hits could provide biological insight into how the
plasma lipoproteins and lipids are affected by these novel
loci. In a mouse model, they validated the associations of
selected genes (i.e., Galnt2, Ppp1r3b and Ttc39b) with pre-
viously unknown or unclear mechanistic links to lipid
metabolism. The abilities of the GWASs to discover SNPs
that affect lipid traits and the observation that only a small
fraction of these SNPs affect coronary atherosclerosis sug-
gest that the lipid traits have different end-point diseases
and do not work through the same pathological mecha-
nisms when they are perturbed.
In 2013, to increase the power to detect variants that
occur at low frequencies and exert major effects on lipid
levels, the Global Lipids Genetics Consortium conducted the
largest GWAS.28 This consortium combined 60 studies for a
total of more than 188,000 participants of European ancestry
to search for variants that affect the lipid traits and their
associated phenotypes. The authors were able to identify
62 new loci in protein-coding regions (functional variants)
that affect blood lipid levels, which brought the total number
of loci that have been associated with lipid traits via GWAS
investigations to 157 variants. These loci are associated with
increased risks of CAD or metabolic disorders. One of the
interesting variants they discovered is near the human
orthologue of the GPR146 gene and is associated with high
levels of total cholesterol and thus provided a new pharma-
cological target for reducing cholesterol and possibly
improving CAD control.From GWAS variants to new biological insights and
functions
In another biological validation of the top GWAS hits,
the same group functionally characterized a non-coding
variant at the SORT1 gene.23 This locus on chromosome
1p13 has been shown to be strongly associated with LDL-
C25 and the risks of CAD and MI.10,25 However, before its
discovery in a GWAS, the functional linkages of SORT1with LDL-C and metabolism were not known. To provide
further information about the association identified by the
GWAS, these authors used a series of studies of human co-
horts and human-derived hepatocytes to show that the
common noncoding polymorphism at this locus, rs12740374,
alters the hepatic expression of the SORT1 gene. Further-
more, using knockdown and over-expression experiments in
mouse livers, they showed that Sort1 alters the plasma levels
of LDL-C and VLDL by modulating hepatic VLDL secre-
tion. This work provided a novel regulatory pathway of li-
poprotein metabolism and a new avenue for therapeutic
approaches to reducing the increased risk of MI that results
from alterations to this pathway. Collectively, these two
studies indicated the power of GWASs for identifying vari-
ants that might alter gene function and increase disease risk
through novel pathways.
In 2011, The IBC 50K CAD Consortium conducted a
large and systematic of CAD risk candidate gene study that
included analyses of many rare and functional variants.29
The authors identified novel variants at LIPA, TRIB1,
and ABCG5/ABCG8. The functional significances of
these variants are supported by gene expression data or
demonstrated effects on lipid levels. These are variants of
novel genes that are associated with the risk of CAD and
thus might help to improve our understanding of the
aetiopathologies of cardiovascular disease and identify
new targets and pathways for therapeutic approaches
that address the functional aspects of those
aetiopathologies.
Around the same time, a large meta-analysis (14 GWAS
investigations of CAD and MI) comprising 22,233 CAD
cases and 64,762 controls13 was conducted by the
CARDIoGRAM. Ten loci that had previously been
associated with the risk of CAD at the genome-wide signif-
icance level reached the same threshold of significance in the
initial meta-analysis performed by the CARDIoGRAM (i.e.,
SORT1, MIA3, WDR12, MRAS, PHACTR1, LPA, 9p21,
CXCL12, LDLR, and MRPS6). At least 4 of these loci are
related to LDL-C. Most importantly, the CARDIoGRAM
identified 13 novel loci that are related to CAD. Two of these
novel loci, 9p34.2 (near ABO) and 11q23.3 (near ZNF259,
APOA5, and A4-C3-A1), are associated with plasma LDL-C
levels.
Many GWAS studies suffer the limitation of a lack of
functional information about the identified lipid-associated
loci. However, GWAS investigations provide a fertile clin-
ical background for functional studies of promising variants
that exert substantial effect on lipids and associated cardio-
vascular events. A remarkable large-scale functional study
was performed by Blattman et al. to functionally analyse 133
candidate genes in close proximity to 56 loci that had pre-
viously been reported to be strongly associated with lipids
and CAD-related factors, such as atherosclerosis and MI,
using the RNA interference (RNAi) approach.30 The
knockdowns revealed that more than 40% of these genes
were involved in LDL-C metabolism. Furthermore, these
authors demonstrated previously unknown lipid regulatory
roles for several genes (e.g., FAM174A, CXCL12, TBL2,
PAFAH1B1, and SEZ6L). Unbiased yet resourceful func-
tional studies are required to follow-up on these GWAS
findings. Such studies will help to establish the foundation
for the development of new pharmaceutical interventions
N.A.M. Almontashiri and M. Hannan 269that target the genes that are involved in pathological lipid
regulation and increased cardiovascular burden.
Conclusion
In conclusion, it is notable that seven of the 36 risk loci
that have thus far been found to be associated with CAD or
MI exert their effects by increasing cholesterol levels,31
which indicates the importance of lipoproteins in the
process of atherosclerosis. The independent associations of
some of these loci with either CAD or MI indicate that
specific genetic loci might promote the development of
coronary atherosclerosis, whereas others might lead to MI
in the presence of CAD. These GWASs have identified
risk loci that are near or within genes, such as PCSK9
and LDLR, which are known to affect lipoprotein
metabolism, which proves the validity and authenticity of
GWASs. In contrast, some GWAS investigations have
identified novel CAD and lipid metabolism genes, such as
SORT1, that were not previously known to affect lipid
metabolism. Such findings illustrate the innovative and
powerful characteristics of GWASs. Additional
approaches, such as whole-exome sequencing, are required
to identify additional independent variants in genes that are
known to affect plasma lipoprotein levels and increase the
risk of CAD through GWASs. Such approaches in combi-
nation with GWAS findings will help us to better calculate
the risk scores conferred by these loci. However, extensive
functional and biological characterizations are required to
decode the importance of many of these risk loci to maxi-
mize their usefulness in the identification of new regulatory
pathways and consequently new targets for the treatment of
dyslipidaemia and the reduction of the risks for heart
diseases.23,25
Recommendations
In view of the increasing incidence of CAD in the Saudi
population, in addition to replicating these GWAS finding, it
would be worthwhile to apply the GWAS approach to
identify novel genetic risk factors and analyse the results in
relation to the dietary/metabolic data of the patients in the
country to better understand the gene-environment in-
teractions that lead to CAD. Projects that involve exome and
candidate gene sequencing for Mendelian and familiar dis-
orders will be required to identify consanguinity-related
diseases and mutations in the Saudi population that will
not be accounted for by GWAS. Such knowledge will
certainly aid the identification of individuals at risk and the
planning of preventive strategies.
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